Exalenz Bioscience Ltd.

Fast Facts

Business
Exalenz provides hepatologists and gastroenterologists with advanced tools for the diagnosis and management of a wide range of conditions in the field of liver health and gastroenterology.

BreathID
The BreathID System is an advanced continuous, automatic, and real-time breath-testing platform that enables the assessment of liver function (hepatic impairment), gastric emptying, and the detection of the presence of the Helicobacter pylori bacteria.

Shares
The company`s stock is traded on the Tel Aviv Stock Exchange (TASE) in Israel. Its ticker symbol is EXEN.

Regulatory

  • USA: The BreathID System is intended for use in the qualitative detection of H. pylori (It has an approved 510(K) and an approved NDA for the 13 C-urea Tablet and Citrica Powder ) . Other applications are limited by Federal (of United States) Law to Investigational Use only.
  • Out of US : The BreathID System has a CE mark in the European Union ( for assessing Helicobacter pylori, Liver Function, and Gastric Emptying Rate ) and and Israel .
2010 Exalenz Bioscience Ltd. All Rights Reserved
Developed by Moonsite

Disclaimer: In the USA, The BreathID System is intended for use in the qualitative detection of H. pylori. It has an approved 510(K) and an approved NDA for the 13 C-urea Tablet and Citrica Powder . Other applications are limited by Federal (of United States) Law to Investigational Use only. In Europe: The BreathID System has a CE approval for assessing Helicobacter pylori, Liver Function, and Gastric Emptying Rate.